Premium
The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus
Author(s) -
Kootte R. S.,
Vrieze A.,
Holleman F.,
DallingaThie G. M.,
Zoetendal E. G.,
de Vos W. M.,
Groen A. K.,
Hoekstra J. B. L.,
Stroes E. S.,
Nieuwdorp M.
Publication year - 2012
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2011.01483.x
Subject(s) - obesity , gut flora , type 2 diabetes mellitus , microbiome , gut microbiome , diabetes mellitus , fecal bacteriotherapy , biology , type 2 diabetes , insulin resistance , bioinformatics , antibiotics , medicine , immunology , endocrinology , microbiology and biotechnology , clostridium difficile
Obesity and type 2 diabetes mellitus (T2DM) are attributed to a combination of genetic susceptibility and lifestyle factors. Their increasing prevalence necessitates further studies on modifiable causative factors and novel treatment options. The gut microbiota has emerged as an important contributor to the obesity—and T2DM—epidemic proposed to act by increasing energy harvest from the diet. Although obesity is associated with substantial changes in the composition and metabolic function of the gut microbiota, the pathophysiological processes remain only partly understood. In this review we will describe the development of the adult human microbiome and discuss how the composition of the gut microbiota changes in response to modulating factors. The influence of short‐chain fatty acids, bile acids, prebiotics, probiotics, antibiotics and microbial transplantation is discussed from studies using animal and human models. Ultimately, we aim to translate these findings into therapeutic pathways for obesity and T2DM in humans.